| Literature DB >> 26658738 |
Mary L Hamilton1, Joanna Warwick2, Anya Terry2, Michael J Allen2, Johnathan A Napier1, Olga Sayanova1.
Abstract
The marine diatom Phaeodactylum tricornutum can accumulate up to 30% of the omega-3 long chain polyunsaturated fatty acid (LC-PUFA) eicosapentaenoic acid (EPA) and, as such, is considered a good source for the industrial production of EPA. However, P. tricornutum does not naturally accumulate significant levels of the more valuable omega-3 LC-PUFA docosahexaenoic acid (DHA). Previously, we have engineered P. tricornutum to accumulate elevated levels of DHA and docosapentaenoic acid (DPA) by overexpressing heterologous genes encoding enzyme activities of the LC-PUFA biosynthetic pathway. Here, the transgenic strain Pt_Elo5 has been investigated for the scalable production of EPA and DHA. Studies have been performed at the laboratory scale on the cultures growing in up to 1 L flasks a 3.5 L bubble column, a 550 L closed photobioreactor and a 1250 L raceway pond with artificial illumination. Detailed studies were carried out on the effect of different media, carbon sources and illumination on omega-3 LC-PUFAs production by transgenic strain Pt_Elo5 and wild type P. tricornutum grown in 3.5 L bubble columns. The highest content of DHA (7.5% of total fatty acids, TFA) in transgenic strain was achieved in cultures grown in seawater salts, Instant Ocean (IO), supplemented with F/2 nutrients (F2N) under continuous light. After identifying the optimal conditions for omega-3 LC-PUFA accumulation in the small-scale experiments we compared EPA and DHA levels of the transgenic strain grown in a larger fence-style tubular photobioreactor and a raceway pond. We observed a significant production of DHA over EPA, generating an EPA/DPA/DHA profile of 8.7%/4.5%/12.3% of TFA in cells grown in a photobioreactor, equivalent to 6.4 μg/mg dry weight DHA in a mid-exponentially growing algal culture. Omega-3 LC-PUFAs production in a raceway pond at ambient temperature but supplemented with artificial illumination (110 μmol photons m-2s-1) on a 16:8h light:dark cycle, in natural seawater and F/2 nutrients was 24.8% EPA and 10.3% DHA. Transgenic strain grown in RP produced the highest levels of EPA (12.8%) incorporated in neutral lipids. However, the highest partitioning of DHA in neutral lipids was observed in cultures grown in PBR (7.1%). Our results clearly demonstrate the potential for the development of the transgenic Pt_Elo5 as a platform for the commercial production of EPA and DHA.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26658738 PMCID: PMC4681182 DOI: 10.1371/journal.pone.0144054
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The effect of light intensity on omega-3 LC-PUFAs accumulation_in Pt_Elo5 transgenic cultures grown in 3.5 L bubble columns.
Cellular growth of WT (Pt_WT) and transgenic strain Pt_Elo5 cultivated under 16:8 light: dark cycle (a) and continuous light (b). Fatty acid composition of WT and transgenic Pt_Elo5 strains grown under 16:8 light: dark cycle and continuous light (c). Values are the average of three experiments (± standard error). Arrows indicate days in culture when cells were harvested.
Fig 2Effect of bicarbonate supplementation and CO2 bubbling on omega-3 LC-PUFAs production.
Cells were grown in IO+F/2 N under constant light in 3.5 L bubble column and analysed at stationary phase. Cellular growth of WT (Pt_WT) and transgenic strain Pt_Elo5 cultivated in the presence of bicarbonate (a) or CO2. Fatty acid composition of WT and transgenic Pt_Elo5 strains grown in the presence of NaHCO3 or CO2 (c). Values are the average of three experiments (± standard error). Arrows indicate day in culture when cells were harvested.
Fig 3Fatty acid composition of transgenic Pt_Elo5 cells grown in PBR at 16:8 h conditions in IO+F/2 medium.
a) Cell concentration, b) Fatty acid composition. Arrows indicate days in culture when cells were harvested.
Fig 4Fatty acid composition of transgenic Pt_Elo5 cells grown in Raceway Pond at 16:8 h conditions in NSW+F2 medium.
a) Cell concentration, b) Fatty acid composition. Arrows indicate day of cultivation when cells were harvested.
Fatty acid composition of total lipids, neutral lipids and polar lipids isolated from Pt_WT and Pt_Elo5 grown in different cultivation systems (mol %).
| 14:0 | 16:0 | 16:1 | 18:0 | 18:1 | EPA | DPA | DHA | 24:0 | Others | |
|---|---|---|---|---|---|---|---|---|---|---|
| 100ml | ||||||||||
|
| ||||||||||
| Cells | 5.6±0.4 | 17.3±0.5 | 37.3±1.7 | 0.4±0.1 | 6.2±0.4 | 21.8±0.6 | nd | 1.4±0.2 | 1.7±0.6 | 6.5±0.3 |
| PL | 8.0±0.7 | 14.2±0.6 | 20.3±0.9 | 1.1±0.4 | 12.7±2.8 | 24.8±0.7 | nd | 8.3±1.1 | 3.1±0.1 | 0.4±0.2 |
| GL | 1.5±0.1 | 14.8±0.1 | 27.7±0.6 | 8.5±0.8 | 5.2±0.8 | 34.9±0.7 | nd | 0.5±0.1 | 0.2±0.2 | 0.7±0.2 |
| NL | 3.7±0.1 | 18.6±0.3 | 46.1±0.8 | 3.4±0.9 | 7.6±0.4 | 15.7±0.6 | nd | 0.5±0.1 | 0.5±0.1 | 0.4±0.1 |
|
| ||||||||||
| Cells | 6.4±0.6 | 17.1±0.8 | 37.2±2.4 | 0.3±0.1 | 5.4±0.5 | 11.1±1.1 | 1.7±0.1 | 8.0±0.7 | 1.3±0.3 | 6.7±0.3 |
| PL | 7.2±1.6 | 16.4±1.7 | 18.2±2.0 | 2.3±1.6 | 4.5±0.3 | 6.9±0.4 | 4.6±0.8 | 28.8±3.6 | 3.1±0.5 | 0.9±0.1 |
| GL | 1.6±0.4 | 13.8±2.7 | 29.0±2.2 | 9.2±1.3 | 4.7±1.2 | 27.7±1.6 | 0.5±0.1 | 2.6±0.1 | 0.3±0.1 | 8.0±0.8 |
| NL | 3.4±0.3 | 17.9±0.6 | 45.4±0.3 | 3.2±0.3 | 8.34±1.9 | 4.9±0.2 | 2.0±0.1 | 5.4±0.5 | nd | 4.2±0.1 |
|
| ||||||||||
|
| ||||||||||
| Cells | 4.7±0.4 | 24.7±1.2 | 31.8±1.8 | 0.5±0.1 | 10.4±1.9 | 20.7±2.2 | 1.3±0.1 | 0.7±0.7 | 0.1±0.1 | 2.1±0.1 |
| PL | 7.3±0.7 | 18.6±1.0 | 16.5±0.5 | 1.2±0.1 | 14.7±0.5 | 25.8±1.9 | nd | 2.9±1.4 | 4.2±1.0 | 5.2±0.1 |
| GL | 2.4±0.1 | 24.2±0.2 | 27.0±0.8 | 11.5±0.1 | 3.0±0.2 | 21.6±0.3 | nd | 0.3±0.1 | 0.2±0.2 | 6.7±0.5 |
| NL | 4.4±0.1 | 29.9±0.1 | 38.0±0.1 | 2.6±0.3 | 2.4±0.1 | 11.7±0.1 | nd | 0.4±0.1 | nd | 1.9±0.1 |
|
| ||||||||||
|
| 6.4±0.2 | 17.9±1.7 | 31.3±0.4 | 0.5±0.1 | 5.21±0.1 | 16.1±0.9 | 4.7±0.7 | 10.0±0.7 | 1.5±0.1 | 2.3±0.1 |
| PL | 9.9±0.5 | 19.2±0.1 | 19.5±0.2 | 0.9±0.1 | 4.1±0.1 | 8.4±0.5 | 8.4±0.8 | 18.7±0.8 | 5.2±0.2 | 2.0±0.1 |
| GL | 2.3±0.1 | 21.0±0.6 | 30.0±0.6 | 9.8±0.4 | 2.6±0.1 | 24.0±1.0 | 0.7±0.4 | 1.8±0.2 | 0.4±0.1 | 5.0±0.2 |
| NL | 4.8±0.4 | 28.5±1.0 | 39.0±1.0 | 3.1±0.3 | 1.9±0.6 | 7.8±0.9 | 2.3±0.1 | 3.6±0.1 | nd | 2.0±0.2 |
|
| ||||||||||
| Cells | 6.6±0.6 | 19.8±0.3 | 34.1±1.1 | 0.37±0.1 | 6.3±0.3 | 8.7±0.5 | 4.5±0.3 | 12.3±0.7 | 0.4±0.1 | 5.3±0.2 |
| PL | 14.7±0.4 | 20.3±0.4 | 20.5±0.3 | 0.4±0.2 | 4.4±0.1 | 6.0±0.5 | 4.5±0.5 | 16.4±0.6 | 1.1±0.5 | 3.6±0.1 |
| GL | 4.6±0.4 | 16.1±0.2 | 34.8±0.1 | 4.7±0.5 | 3.8±0.2 | 21.8±0.5 | 0.9±0.1 | 2.9±0.1 | 0.7±0.5 | 2.1±0.1 |
| NL | 6.8±0.1 | 18.9±0.8 | 31.2±0.5 | 7.7±1.1 | 5.5±0.1 | 6.7±0.2 | 3.4±0.1 | 7.1±0.1 | 1.3±0.1 | 3.0±0.1 |
|
| ||||||||||
| Cells | 7.4±0.3 | 14.1±0.3 | 24.5±1.1 | nd | 3.4±0.7 | 24.8±0.3 | 3.3±0.2 | 10.3±1.0 | nd | 10.4±0.1 |
| PL | 9.4±0.7 | 15.5±2.1 | 25.0±1.5 | 2.1±0.3 | 5.7±0.7 | 10.3±1.9 | 6.1±0.3 | 16.0±2.0 | 1.8±0.2 | 6.5±0.3 |
| GL | 2.4±0.1 | 22.5±2.3 | 16.0±0.6 | 16.5±2.5 | 2.2±0.4 | 19.9±3.4 | 0.6±0.1 | 2.3±0.2 | 0.3±0.1 | 13.6±0.4 |
| NL | 3.9±0.2 | 21.9±0.25 | 13.0±0.2 | 31.1±0.7 | 4.1±0.7 | 12.8±1.0 | 0.4±0.1 | 0.6±0.1 | nd | 10.7±0.8 |
+ Other lipids Lipids comprising <2% of the total algal lipids. GL, glycolipid; NL, neutral lipid; PL, phospholipid.
* Average of PBR samples from day 25, 35 and 43.
**Average of RP samples from day 3 and 5.
Fig 5Comparison of omega-3 LC-PUFAs content in different production systems.